AI Article Synopsis
- Bacterial vaginosis (BV) is a condition that can lead to serious reproductive health issues in women, including increased risk for sexually transmitted infections.
- The traditional method of diagnosing BV requires skilled personnel to analyze vaginal swab samples under a microscope, highlighting the need for new diagnostic approaches.
- A new immunosensing platform targeting the BV biomarker sialidase demonstrates a faster, cheaper, and more efficient method for diagnosis, achieving high sensitivity and specificity in clinical evaluations.
Article Abstract
Bacterial vaginosis (BV) affects reproductive-age women and can lead to pelvic inflammatory disease, postpartum endometritis, and preterm labor/delivery and predisposes the infection of sexually transmitted diseases. Typically, BV diagnosis involves the analysis of vaginal swab samples microscopy operated by highly skilled personnel. Hence, novel approaches for BV diagnosis are an existing need. In response, the first immunosensing platform targeting sialidase, a BV biomarker, is reported. The nanophotonic operational principle of this biosensing platform allows for a cheaper, faster, and simpler analysis when compared with an indirect enzyme-linked immunosorbent assay (ELISA). The clinical evaluation of such a nanotechnology is highlighted, where 162 vaginal swab samples were analyzed with high sensitivity and specificity (96.29%, respectively). The resulting nanoimmunosensing platform offers a resourceful approach to perform a timely BV diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887842 | PMC |
| http://dx.doi.org/10.1021/acsptsci.0c00211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!